, Volume 16, Issue 3, pp 297–305 | Cite as

Serum fetuin-A levels are associated with serum triglycerides before and 6 months after bariatric surgery

  • Christos G. Verras
  • Georgios A. Christou
  • Yannis V. Simos
  • George D. Ayiomamitis
  • Andreas J. Melidonis
  • Dimitrios N. KiortsisEmail author
Research paper



The elucidation of the changes of fetuin-A in the context of bariatric surgery.


Twenty obese patients (8 males, 12 females; body mass index = 42.5±3.4 kg/m2) were studied at baseline and 6 months after bariatric surgery.


Serum fetuin-A levels did not differ with regard to the presence of each individual component of the Metabolic Syndrome (MetS) at baseline, except for hypertriglyceridaemia [increased serum fetuin-A levels (p=0.011)]. Circulating fetuin-A was positively correlated with serum triglycerides (TG) (r=0.461, p=0.047) and negatively correlated with serum globulins (r=−0.477, p=0.033) and C-reactive protein (CRP) (r=−0.604, p=0.010), while it independently predicted TG at baseline. Circulating fetuin-A did not change during the 6 months either in the whole population or in the subgroups of patients who were positive for each individual component of MetS at baseline and negative for this component at 6 months of follow-up, except for hypertriglyceridaemia [reduction of serum fetuin-A levels (p=0.046)]. The subgroup of patients with a decrease in circulating fetuin-A during the 6 months was characterized by a smaller reduction of serum globulins (p=0.003) and CRP (p=0.049). The change in serum fetuin-A levels over the 6 months was positively correlated with the change in TG (r=0.592, p=0.006) and negatively correlated with the change in serum globulins (r=−0.523, p=0.018) and CRP (r=−.494, p=0.037).


Circulating fetuin-A predicted serum triglycerides before as well as 6 months after bariatric surgery.

Key words

Metabolic syndrome Obesity Weight loss 


  1. 1.
    Dabrowska AM, Tarach JS, Wojtysiak-Duma B, Duma D, 2015 Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 159: 352–359.CrossRefGoogle Scholar
  2. 2.
    Maréchal C, Schlieper G, Nguyen P, et al, 2011 Serum fetuin-A levels are associated with vascular calcifications and predict cardiovascular events in renal transplant recipients. Clin J Am Soc Nephrol 6: 974–985.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Mathews ST, Srinivas PR, Leon MA, Grunberger G, 1997 Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. Life Sci. 61: 1583–1592.CrossRefGoogle Scholar
  4. 4.
    Song A, Xu M, Bi Y, et al, 2011 Serum fetuin-A associates with type 2 diabetes and insulin resistance in Chinese adults. PLoS One 6: e19228.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Aroner SA, Mukamal KJ, St-Jules DE, et al, 2017 Fetuin-A and Risk of Diabetes Independent of Liver Fat Content: The Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 185: 54–64.CrossRefGoogle Scholar
  6. 6.
    Xu Y, Xu M, Bi Y, et al, 2011 Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis 216: 180–186.CrossRefGoogle Scholar
  7. 7.
    Yin L, Cai WJ, Chang XY, et al, 2014 Association between fetuin-A levels with insulin resistance and carotid intima-media thickness in patients with new-onset type 2 diabetes mellitus. Biomed Rep 2: 839–842.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ou HY, Yang YC, Wu HT, Wu JS, Lu FH, Chang CJ, 2012 Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose. J Clin Endocrinol Metab 97: 4717–4723.CrossRefGoogle Scholar
  9. 9.
    Ismail NA, Ragab S, El Dayem SM, et al, 2012 Fetuin-A levels in obesity: differences in relation to metabolic syndrome and correlation with clinical and laboratory variables. Arch Med Sci 8: 826–833.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Choi KM, Han KA, Ahn HJ, et al, 2013 The effects of caloric restriction on fetuin-A and cardiovascular risk factors in rats and humans: a randomized controlled trial. Clin Endocrinol (Oxf) 79: 356–363.CrossRefGoogle Scholar
  11. 11.
    Blüher M, Rudich A, Klöting N, et al, 2012 Two patterns of adipokine and other biomarker dynamics in a long-term weight loss intervention. Diabetes Care 35: 342–349.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH, 2010 Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 33: 1134–1139.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Reinehr T, Roth CL, 2008 Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab 93: 4479–4485.CrossRefGoogle Scholar
  14. 14.
    Brix JM, Stingl H, Höllerl F, Schernthaner GH, Kopp HP, Schernthaner G, 2010 Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab 95: 4877–4881.CrossRefGoogle Scholar
  15. 15.
    Yang PJ, Ser KH, Lin MT, et al, 2015 Diabetes Associated Markers After Bariatric Surgery: Fetuin-A, but Not Matrix Metalloproteinase-7, Is Reduced. Obes Surg 25: 2328–2334.CrossRefGoogle Scholar
  16. 16.
    König D, Zdzieblik D, Deibert P, Berg A, Gollhofer A, Büchert M, 2015 Internal Fat and Cardiometabolic Risk Factors Following a Meal-Replacement Regimen vs Comprehensive Lifestyle Changes in Obese Subjects. Nutrients 7: 9825–9833.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Pournaras DJ, Le Roux CW, 2009 The effect of bariatric surgery on gut hormones that alter appetite. Diabetes Metab 35(6 Pt 2): 508–512.CrossRefGoogle Scholar
  18. 18.
    Kahraman A, Sowa JP, Schlattjan M, et al, 2013 Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients. Clin Sci (Lond) 125: 391–400.CrossRefGoogle Scholar
  19. 19.
    Tamboli RA, Hossain HA, Marks PA, et al, 2010 Body composition and energy metabolism following Rouxen-Y gastric bypass surgery. Obesity (Silver Spring) 18: 1718–1724.CrossRefGoogle Scholar
  20. 20.
    Carey DG, Pliego GJ, Raymond RL, 2006 Body composition and metabolic changes following bariatric surgery: effects on fat mass, lean mass and basal metabolic rate: six months to one-year follow-up. Obes Surg 16: 1602–1608.CrossRefGoogle Scholar
  21. 21.
    Himmetoglu S, Teksoz S, Zengin K, Yesim T, Taskın M, Dincer Y, 2013 Serum levels of fetuin A and 8-hydroxydeoxyguanosine in morbidly obese subjects. Exp Clin Endocrinol Diabetes 121: 505–508.CrossRefGoogle Scholar
  22. 22.
    Mathews ST, Rakhade S, Zhou X, Parker GC, Coscina DV, Grunberger G, 2006 Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun 350: 437–443.CrossRefGoogle Scholar
  23. 23.
    Mathews ST, Singh GP, Ranalletta M, et al, 2002 Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 51: 2450–2458.CrossRefGoogle Scholar
  24. 24.
    Selvin E, Paynter NP, Erlinger TP, 2007 The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med 167: 31–39.CrossRefGoogle Scholar
  25. 25.
    Obuchi A, Adachi H, Enomoto M, et al, 2014 High plasma fetuin-A levels are associated with metabolic syndrome among males but not females in a Japanese general population. Diabetes Res Clin Pract 106: 128–135.CrossRefGoogle Scholar
  26. 26.
    Kaess BM, Enserro DM, McManus DD, et al, 2012 Cardiometabolic correlates and heritability of fetuin-A, retinol-binding protein 4, and fatty-acid binding protein 4 in the Framingham Heart Study. J Clin Endocrinol Metab 97: E 1943–1947.CrossRefGoogle Scholar
  27. 27.
    Tinahones FJ, Garrido-Sánchez L, Murri M, García-Fuentes E, Cardona F, 2013 Particular characteristics of the metabolic syndrome in patients with morbid obesity. Endocrinol Nutr 60: 127–135.CrossRefGoogle Scholar
  28. 28.
    Jensen MD, Ryan DH, Apovian CM, et al, 2014 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129: 25 Suppl 2: 102–138.CrossRefGoogle Scholar
  29. 29.
    Roos M, von Eynatten M, Heemann U, Rothenbacher D, Brenner H, Breitling LP, 2010 Serum fetuin-A, cardiovascular risk factors, and six-year follow-up outcome in patients with coronary heart disease. Am J Cardiol 105: 1666–1672.CrossRefGoogle Scholar
  30. 30.
    Yin L, Cai WJ, Zhu LY, et al, 2015 Association of plasma Fetuin-A and clinical characteristics in patients with new-onset type 2 diabetes mellitus. Int J Clin Exp Med 8: 991–999.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteier M, Whooley MA, 2006 Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. 113: 1760–1677.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Liu A, Lamendola C, Ariel D, et al, 2015 Usefulness of fetuin-A to predict risk for cardiovascular disease among patients with obstructive sleep apnea. Am J Cardiol 116: 219–224.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Noureldein MH, Abd El-Razek RS, El-Hefnawy MH, El-Mesallamy HO, 2015 Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis. Diabetes Res Clin Pract 109: 513–520.CrossRefGoogle Scholar
  34. 34.
    Ozyazgan S, Karaoglu K, Kurt A, et al, 2013 Effects of omega-3 polyunsaturated fatty acid supplementation on serum fetuin-A levels in type 2 diabetic patients. Minerva Med 104: 287–293.PubMedGoogle Scholar
  35. 35.
    Kaushik SV, Plaisance EP, Kim T, et al, 2009 Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. Diabetes Metab Res Rev 25: 427–434.CrossRefGoogle Scholar
  36. 36.
    Cayarte AJ, Kumbla L, Subbiah MT, 1990 Marked acceleration of exogenous fatty acid incorporation into cellular triglycerides by fetuin. J Biol Chem 265: 5883–5888.Google Scholar
  37. 37.
    Ishibashi A, Ikeda Y, Ohguro T, et al, 2010 Serum fetuin-A is an independent marker of insulin resistance in Japanese men. J Atheroscler Thromb 17: 925–933.CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2017

Authors and Affiliations

  • Christos G. Verras
    • 1
  • Georgios A. Christou
    • 2
  • Yannis V. Simos
    • 2
  • George D. Ayiomamitis
    • 3
  • Andreas J. Melidonis
    • 1
  • Dimitrios N. Kiortsis
    • 2
    Email author
  1. 1.Diabetes CenterTzanio General HospitalPiraeusGreece
  2. 2.Laboratory of Physiology, Medical SchoolUniversity of IoanninaIoanninaGreece
  3. 3.2nd Department of SurgeryTzanion General HospitalPiraeusGreece

Personalised recommendations